Shopping Cart
Remove All
Your shopping cart is currently empty
Retifanlimab
(Synonyms: MGA-012, MGA012, INCMGA-0012, INCMGA0012, AEX-1188, AEX1188) Copy Product Info
🥰Excellent
Synonyms: MGA-012, MGA012, INCMGA-0012, INCMGA0012, AEX-1188, AEX1188
Catalog No. T77180 Copy Product Info
🥰Excellent
Retifanlimab (MGA-012) is a blocking antibody that targets programmed cell death protein 1 (PD-1). By binding to the PD-1 receptor on the surface of T cells, retifanlimab blocks its interaction with the ligands PD-L1 and PD-L2, thereby reversing the immune suppression mediated by the PD-1 pathway and exerting an antitumor effect. Retifanlimab is indicated for the treatment of Merkel cell carcinoma.
Cas No. 2079108-44-2
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $198 | - | In Stock | |
| 5 mg | $516 | - | In Stock | |
| 10 mg | $790 | - | In Stock | |
| 25 mg | $1,220 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.56% (SEC-HPLC)
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Retifanlimab (MGA-012) is a blocking antibody that targets programmed cell death protein 1 (PD-1). By binding to the PD-1 receptor on the surface of T cells, retifanlimab blocks its interaction with the ligands PD-L1 and PD-L2, thereby reversing the immune suppression mediated by the PD-1 pathway and exerting an antitumor effect. Retifanlimab is indicated for the treatment of Merkel cell carcinoma. |
| Targets & IC50 | PD-1 (human):3.71 ng/mL (EC50) |
| In vitro | Retifanlimab is an anti-programmed cell death protein-1 (anti-PD-1) monoclonal antibody (mAb) with EC50 = 3.71 ng/mL. |
| Synonyms | MGA-012, MGA012, INCMGA-0012, INCMGA0012, AEX-1188, AEX1188 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | PDCD1/PD-1/CD279 |
| Molecular Weight | 148.28 kDa |
| Cas No. | 2079108-44-2 |
| Isotype | Human IgG4SP kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Preview
Related Tags: Retifanlimab chemical structure | Retifanlimab in vitro | Retifanlimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.